Design: International prospective cohort (PROCLIPI), 46 referral centres
Population: 277 patients with stage IIB to IVB mycosis fungoides or Sézary syndrome
Primary outcome: Progression-free survival and best objective response
Effect: Median PFS 4.64 vs 2.72 vs 0.89 years; high vs low risk HR 3.84 (95% CI 2.21 to 6.66)

An international prospective cohort in JAMA Dermatology (7 October) analysed 277 patients with advanced mycosis fungoides or Sézary syndrome (stage IIB to IVB) from the PROCLIPI study across 46 referral centres, followed for a median of about 4.75 years. Each was scored at diagnosis on the Cutaneous Lymphoma International Prognostic Index (CLIPI): age over 60, raised serum LDH, N3 nodal status and large-cell transformation in the skin.

Median progression-free survival was 4.64 years at low risk (0 or 1 factor), 2.72 years at intermediate risk (2 factors) and 0.89 years at high risk (3 or 4). Compared with low risk, the hazard of progression or death was 1.45 times higher at intermediate risk and 3.84 times higher at high risk. Adding CLIPI to stage improved prediction, and each extra point was linked to lower odds of a better treatment response (OR 0.62).

TNMB staging is known to discriminate poorly within advanced disease. The four CLIPI items are already collected at diagnosis, so the score costs nothing to calculate and gives a clearer basis for discussing prognosis and for referral to a specialist cutaneous lymphoma service or trial.

At diagnosis of advanced mycosis fungoides or Sézary syndrome, record age, serum LDH, nodal status and any large-cell transformation.
Calculate the CLIPI score from those four items and document the risk group.
Consider early referral to a specialist cutaneous lymphoma team for patients with three or four factors.
Use the score to frame prognosis discussions alongside stage, not instead of it.

Why it matters

Stage alone lumps together patients whose outlook differs several-fold; four routine data points separate them.

The statistics, in plain English

A hazard ratio of 3.84 means the high-risk group progressed or died at nearly four times the rate of the low-risk group. Only 40 patients were high risk, so that estimate has a wide interval (2.21 to 6.66). An odds ratio of 0.62 per point means each extra factor lowered the odds of a better response by about 38%.